Rhythm Pharmaceuticals
setmelanotide
acquired hypothalamic obesity
Countdown
177days
Approval decision · ~ Dec 31, 2026 estimated
What's at stake
A final FDA approval decision on setmelanotide for acquired hypothalamic obesity is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“potential marketing authorization in the second half of 2026”